Why Anti-CD20 Therapy Has Become a Cornerstone of MS Treatment

In "Why Anti-CD20 Therapy Has Become a Cornerstone of MS Treatment" episode, panelists explore the anti-CD20 drug class itself — a group of B-cell depleting therapies that have become the most commonly initiated treatments for MS in the United States. Experts recount that the field initially viewed B-cell targeting as counterintuitive in what was long considered a T-cell-mediated disease. However, experience and trial data have demonstrated that depleting CD19/CD20-positive B cells produces profound downstream immunological effects that dramatically suppress MS disease activity.

In clinical trial data and real-world evidence alike, Dr. Bove notes that over 90–95% of patients on B-cell depleting therapy show no new MRI lesions. When a new lesion does appear in a patient already on anti-CD20 therapy, it merits careful investigation — potentially using advanced sequences such as the central vein sign — to determine whether it represents true MS activity or a lesion from another etiology (hypertension, migraine, aging).

Beyond efficacy, Dr. Bove emphasizes two additional drivers of the class's rise to frontline status: convenience and flexibility. The infrequent dosing schedules — biannual infusion or monthly self-injection — allow patients to "treat their MS and go about their lives," a paradigm shift from the daily or every-other-day injections of platform therapies. The class also offers meaningful flexibility around family planning and travel, with dosing windows less rigidly tied to exact timing than earlier agents.

In the next episode, "Comparing Anti-CD20 Therapies in MS," the panel breaks down the key similarities and differences among available B-cell depleting agents and explains how to present these distinctions to patients.